Bristol-Myers Squibb Co Could Rise a Lot According to The Today’s Call Option Activity

 Bristol Myers Squibb Co Could Rise a Lot According to The Today's Call Option Activity

In today’s session Bristol-Myers Squibb Co (BMY) registered an unusually high (2,074) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious BMY increase. With 2,074 contracts traded and 134844 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: BMY170120C00062500 closed last at: $0.3 or 14.3% down. About 2.51M shares traded hands. Bristol-Myers Squibb Co (NYSE:BMY) has declined 21.89% since April 28, 2016 and is downtrending. It has underperformed by 27.82% the S&P500.

Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on January, 26. They expect $0.65 earnings per share, up 71.05% or $0.27 from last year’s $0.38 per share. BMY’s profit will be $1.09B for 21.40 P/E if the $0.65 EPS becomes a reality. After $0.77 actual earnings per share reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -15.58% negative EPS growth.

Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage

Out of 16 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 8 “Hold”. This means 31% are positive. $80 is the highest target while $52 is the lowest. The $68.90 average target is 23.85% above today’s ($55.63) stock price. Bristol-Myers Squibb Company has been the topic of 34 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The company was downgraded on Friday, August 5 by Morgan Stanley. Barclays Capital maintained the shares of BMY in a report on Friday, September 9 with “Equal-Weight” rating. Societe Generale initiated the stock with “Sell” rating in Wednesday, April 6 report. The firm earned “Hold” rating on Thursday, August 27 by Jefferies. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Neutral” rating by Hilliard Lyons on Monday, May 23. Berenberg downgraded Bristol-Myers Squibb Co (NYSE:BMY) on Thursday, August 11 to “Hold” rating. The rating was upgraded by Piper Jaffray on Monday, August 24 to “Underweight”. As per Friday, April 29, the company rating was maintained by UBS. The stock has “Underweight” rating given by Atlantic Securities on Friday, December 18. On Friday, August 19 the stock rating was maintained by UBS with “Buy”.

According to Zacks Investment Research, “Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.”

Insitutional Activity: The institutional sentiment increased to 1.13 in 2016 Q2. Its up 0.19, from 0.94 in 2016Q1. The ratio improved, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
Shinko Asset Ltd last reported 0% of its portfolio in the stock. Heritage holds 0.56% or 100,420 shares in its portfolio. 1St Source Bancshares, a Indiana-based fund reported 65,954 shares. Jarislowsky Fraser Ltd last reported 1.89 million shares in the company. Mai Management, a Ohio-based fund reported 18,248 shares. Sandy Spring Financial Bank holds 104,315 shares or 0.89% of its portfolio. Oarsman Capital last reported 0.17% of its portfolio in the stock. Moreover, Stevens First Principles Inv Advsr has 0.04% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 777 shares. Excalibur Corp has invested 0.99% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Neuberger Berman Group Incorporated Ltd Limited Liability Company accumulated 0.56% or 5.53M shares. Alyeska Grp Limited Partnership reported 904,791 shares or 0.68% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 0.82% of its portfolio in the stock. Gilman Hill Asset Mgmt Ltd Llc accumulated 15,475 shares or 0.47% of the stock. Charlemagne Limited accumulated 0.25% or 4,347 shares. Cypress Grp owns 92,630 shares or 1.59% of their US portfolio.

Insider Transactions: Since June 14, 2016, the stock had 0 insider buys, and 5 sales for $6.86 million net activity. ANDREOTTI LAMBERTO sold $1.73M worth of stock. Elicker John E sold 11,820 shares worth $859,219.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $93.10 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 27.71 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.

BMY Company Profile

Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

More news for Bristol-Myers Squibb Co (NYSE:BMY) were recently published by: Businesswire.com, which released: “European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the …” on November 22, 2016. Equitiesfocus.com‘s article titled: “Bristol-Myers Squibb Company (NYSE:BMY) Short-Term Price Target At $62.7400” and published on December 01, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment